USPTO serial 79025533
KRINGLE PHARMA
Reviewed by CopyMark Law Group
Reg. 3324812Status 404
- Filing date
- Status date
- Registration date
- Oct 30, 2007
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KRINGLE PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical veterinary preparations for liver diseases, renal disease, nerve system diseases, skin diseases, cardiovascular diseases and cancer; sanitary preparations for medical use; central nervous system stimulants; stimulants in the nature of hair growth stimulant; antipyretic analgesics; anti-epileptics; analeptics; hypnotic sedatives; general anesthetics; anti-motion sickness preparations; preparations acting on the peripheral nervous system; local anesthetics; skeletal muscle relaxants; anhidrotics; pharmaceutical preparations for the treatment of autonomic nervous system diseases; antispasmodics; diaphoretics; pharmaceutical preparations for the treatment of sensory organs diseases; ophthalmic preparations; preparations for otic and nasal use, namely, nasal spray preparations, ear drops; antiallergic medications; antihistamines; cardiovascular treatment preparations; cardiotonics; antihypertensives; vasoconstrictors; pharmaceutical preparations for the treatment of vascular and venous diseases; cerebral hemorrhage prophylactic preparations; antiarrhythmic preparations; diuretics; pharmaceutical products for treating respiratory diseases; respiratory stimulants; anti-cough drops; anti-tussive expectorants; pharmaceutical preparations for the treatment of disease affecting digestive organs; gastrointestinal cleaning agents; evacuants; pharmaceutical preparations for oral care, namely, the treatment of oral inflammation, namely, stomatitis; emetics; medicines for dental purposes, namely, pharmaceutical preparations for the treatment of gingivostomatitis, alveolar abscess, alveoloclasia; antacids; intestinal regulators, namely, gastro-intestinal treatment preparations; antiemetics; castor oil for medical purposes; tooth prophylactics, namely, material for stopping teeth; cholagogues; hormones for medical purposes; thyroid and para-thyroid hormone preparations; mixed hormone preparations; estrogen preparations; pancreas hormone preparations; salivary gland hormone preparations; androgen preparations; pituitary hormone preparations; adrenal hormone preparations; pharmaceutical preparations for the treatment of disease affecting uro-genitial and anal organs; oxytocics; anti-hemorrhoidals; emmenagogues; contraceptives; medicated skin care preparations, pharmaceutical preparations for dermatics and for purulence; pharmaceutical preparations for the treatment of skin infection; antimicrobials for dermatologic use; astringents; anti-inflammatories; analgesics; emollients, namely, medicinal creams for skin care; hair remedies, namely, medicated hair care preparations; medicated baby oils; medicated baby powders; medicated bath preparations; vitamin preparations; cod-liver oil drops; mixed vitamin preparations; vitamin A preparations; vitamin C preparations; vitamin D preparations; vitamin B preparations; multi-vitamin preparations; amino acid preparations for medical purposes; threonine preparations; tryptophane preparations; methionine preparations; lysine preparations; royal jelly for medical purposes; calcium supplements; chondroitin preparations; protein and amino acid preparations for medical purposes; saccharide preparations for treating skin diseases, namely, skin ulcer, injury, burn, scleroderma, dematitis, erythroderma, keratosis, dyschromatosis, lupus erhthematosus; mineral preparations for medical use; anticoagulants; blood substitutes for human and veterinary use; blood plasma; hemostatics; pharmaceutical preparations for conditions affecting metabolism; antidotes; enzyme preparations for medical purposes; lactagogues; lipotropic factor preparations; pharmaceutical preparations for activating cellular function; chlorophyll preparations in the nature of dietary supplements; tumor suppressing agents; anti-cancer preparations; anti-sarcoma preparations; medicated skin care preparations for treating physically caused lesions; pharmaceutical preparations for the treatment of heatstroke; radiation sickness treating agents; pharmaceutical preparations for treating chemically caused disorders, namely, chemical burn and side effect of anticancer drugs; immunosuppresants; pharmaceutical preparations for chlorine-detoxication; pharmaceutical preparations for arsenic-detoxication; pharmaceutical preparations for benzol-detoxication; antibiotic preparations; erythromycin preparations; chioramphenicol preparations; colistin-polymixin preparations; streptomycin preparations; thiolutin preparations; tetracycline preparations; trichomycin preparations; mixed antibiotic preparations; penicillin preparations; chemotherapeutics; antisyphilitics; antituberculous preparations; sulfonamide preparations; antileprotic preparations; biological preparations for medical purposes; antitoxic sera; antitoxins, mixed biological preparations for medical purposes; preparations for biological tests for medical purposes; toxoids; vaccines; preparations for destroying parasites; anthelmintics; ointment bases of the drugs for skin diseases, namely, itching, injury, burn, keloid, dermatitis, eczema, skin ulcer, psoriasis; diagnostic preparations for medical and veterinary use; contrast media for use with X-ray equipment; diagnostic reagents for medical use; diagnostic media for bacteriological cultures; radio-isotope markers for therapeutic or diagnostic use; opium alkaloid preparations; synthetic narcotics; coca alkaloid preparations; mosquito-repellent incenses; germicides and fungicides; rodenticides; insecticides; fumigants; herbicides; insect-repellents; antiseptics | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 17, 2016 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Jun 17, 2016 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 10, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jun 23, 2015 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jun 23, 2015 | INPC | INVALIDATION PROCESSED | — |
| May 31, 2015 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 6, 2015 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 6, 2014 | C71T | CANCELLED SECTION 71 | — |
| Jan 13, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 5, 2009 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 5, 2008 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 4, 2008 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 30, 2008 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 30, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 14, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 25, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 10, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 10, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 18, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 18, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2007 | PAPER RECEIVED | — | |
| Apr 24, 2007 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Mar 17, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 16, 2007 | ALIE | ASSIGNED TO LIE | — |
| Feb 7, 2007 | PAPER RECEIVED | — | |
| Jan 13, 2007 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Dec 20, 2006 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Dec 7, 2006 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Nov 22, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 15, 2006 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 29, 2006 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 29, 2006 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 26, 2006 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 25, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 11, 2006 | NWAP | NEW APPLICATION ENTERED | — |
| Aug 10, 2006 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |